Drug Profile
Research programme: synthetic humanised camelid nanobodies - Curie Institute/THERAVECTYS
Alternative Names: Synthetic humanised camelid single-domain antibodies - Curie Institute/THERAVECTYSLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Curie Institute
- Developer Curie Institute; THERAVECTYS
- Class Immunotherapies; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD27 antigen inhibitors; Checkpoint kinase inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer